ArticleNeurologia medico-chirurgica2025
Radiotherapy Offered Limited Additional Benefits on Cancer-specific Survival for Patients with Resectable Subcutaneous Malignant Peripheral Nerve Sheath Tumors: A Population-based Retrospective Cohort Analysis.
Article in Neurologia medico-chirurgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For resectable malignant peripheral nerve sheath tumors, the additional benefits of radiotherapy remain controversial. This study aims to investigate whether there is an additional benefit of radiotherapy for resectable malignant peripheral nerve sheath tumors. We retrospectively collected data on malignant peripheral nerve sheath tumor cases from the Surveillance, Epidemiology, and End Results database. Overall, 926 malignant peripheral nerve sheath tumor cases occurred in soft tissues, with surgical resection performed in 783 cases. After excluding cases with distant metastasis, incomplete follow-up, rare tumor sites, and unrecorded tumor diameter, 339 malignant peripheral nerve sheath tumor cases with highly complete information were included in the study. Cox analysis and propensity score matching were used to evaluate the prognosis. Cancer-specific survival was selected as the endpoint for this study. Subgroup analyses were applied based on tumor diameters and sites. In both regressions on total and post-propensity score matching data, radiotherapy was not identified as an independent risk factor for cancer-specific survival. Further results from subgroup analyses indicated that radiotherapy was not a significant risk factor for cancer-specific survival in each subgroup of the total study data and the post-propensity score matching data. In conclusion, radiotherapy provided limited benefits on Cancer-specific survival for resectable malignant peripheral nerve sheath tumors. Subgroup analyses based on tumor diameter and location also failed to demonstrate positive outcomes. However, the benefits of radiotherapy for controlling local tumor recurrence still need to be explored through prospective randomized controlled clinical trials in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.